SavedAdd your journal

Journals / Ankara Üniversitesi Eczacılık Fakültesi Dergisi / 2026 / Cilt: 50 Sayı: 3

SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL PYRAZOLE-BARBITURATE HYBRIDS AS ALPHA-GLUCOSIDASE INHIBITORS

YENİ PİRAZOL-BARBİTÜRAT HİBRİTLERİNİN α-GLUKOZİDAZ İNHİBİTÖRLERİ OLARAK SENTEZİ VE BİYOLOJİK DEĞERLENDİRİLMESİ

Beyza Nur Karcı(VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ)0009-0004-8571-9504
Fatih Dönmez(VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ)0000-0003-3958-1028
Burak Kuzu(VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ)0000-0002-7305-7177
Pages
578–591
Publication Date
2026-09-19
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results suggest 17f as a promising candidate for further development as an antidiabetic agent.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Type 2 diabetes is a global health problem marked by chronic hyperglycemia. α-Glucosidase inhibitors help regulate postprandial glucose levels, but current drugs have side effects and limited efficacy.
📊
Key Findings & Data:This study aimed to develop novel pyrazole–barbiturate hybrids as more effective α-glucosidase inhibitors.
💡
Conclusion & Impact:These results suggest 17f as a promising candidate for further development as an antidiabetic agent.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:α-Glukozidaz · barbitürat · doking

Abstract

Objective: Type 2 diabetes is a global health problem marked by chronic hyperglycemia. α-Glucosidase inhibitors help regulate postprandial glucose levels, but current drugs have side effects and limited efficacy. This study aimed to develop novel pyrazole–barbiturate hybrids as more effective α-glucosidase inhibitors. Material and Method: Type 2 diabetes is a global health problem marked by chronic hyperglycemia. α-Glucosidase inhibitors help regulate postprandial glucose levels, but current drugs have side effects and limited efficacy. This study aimed to develop novel pyrazole–barbiturate hybrids as more effective α-glucosidase inhibitors. Result and Discussion: Only compound 17f, featuring a 4-biphenyl group, showed strong α-glucosidase inhibition (IC₅₀=35.28±1.14 µM), outperforming the reference drug acarbose. The other compounds were inactive (IC₅₀>200 µM). The findings highlight the importance of aromatic bulk and hydrophobicity in enzyme binding. Molecular docking supported the observed activity of 17f, indicating favorable π–π stacking and hydrophobic interactions. These results suggest 17f as a promising candidate for further development as an antidiabetic agent.

Özet

Amaç: Tip 2 diyabet, kronik hiperglisemi ile karakterize edilen ve dünya genelinde önemli bir sağlık sorunu olan metabolik bir hastalıktır. α-Glukozidaz inhibitörleri postprandiyal kan şekeri düzeylerinin kontrolünde önemli rol oynasa da, mevcut ilaçlar çeşitli yan etkiler ve sınırlı etkinlik göstermektedir. Bu çalışmada, daha etkili α-glukozidaz inhibitörleri geliştirmek amacıyla yeni pirazol-barbitürat hibrit bileşikleri tasarlanmıştır. Gereç ve Yöntem: Hedef moleküller rasyonel tasarımla sentezlenmiş ve NMR ile HRMS analizleri kullanılarak karakterize edilmiştir. α-Glukozidaz enzimine karşı inhibitör etkileri p-NPG substratı kullanılarak in vitro ortamda değerlendirilmiştir. Enzim aktivitesi spektrofotometrik olarak ölçülmüş ve IC₅₀ değerleri hesaplanmıştır. Sonuç ve Tartışma: Sentetik türevlerden yalnızca 4-bifenil grubu taşıyan 17f bileşiği güçlü α-glukozidaz inhibitör aktivitesi göstermiştir (IC 50 =35.28±1.14 µM) ve referans ilaç akarbozdan daha etkili bulunmuştur. Diğer türevler (IC 50 >200 µM) etkisizdir. Aromatik hacim ve hidrofobikliğin enzim bağlanmasında önemli rol oynadığı gözlemlenmiştir. Moleküler kenetlenme çalışmaları, 17f’in enzim aktif bölgesindeki π–π etkileşimleri ve hidrofobik bağlanma ile uyumlu olduğunu desteklemiştir. Bulgular, 17f bileşiğini antidiabetik ajan geliştirme süreci için potansiyel bir aday olarak ortaya koymaktadır.

🔖

Cite This Article

Karcı, B. N., Dönmez, F., Kuzu, B. (2026). SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL PYRAZOLE-BARBITURATE HYBRIDS AS ALPHA-GLUCOSIDASE INHIBITORS. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 50 Sayı: 3, 578–591. https://doi.org/10.33483/jfpau.1780807

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (25)

  1. Deepthi, B., Sowjanya, K., Lidiya, B., et al. (2017). A modern review of diabetes mellitus: An annihilatory metabolic disorder. Silico In Vitro Pharmacology, 3(1), 1-5. [CrossRef]
  2. Chen, L., Magliano, D.J., Zimmet, P.Z. (2012). The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nature Reviews Endocrinology, 8(4), 228-236. [CrossRef]
  3. Zheng, Y., Ley, S.H., Hu, F.B. (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology, 14(2), 88-98. [CrossRef]
  4. Bhatnagar, A., Mishra, A. (2022). α-Glucosidase inhibitors for diabetes/blood sugar regulation. Eds: Maheshwari, V.L., Patil, R.H. In Natural Products as Enzyme Inhibitors: An Industrial Perspective, Springer, Singapore, 269-283. [CrossRef]
  5. Kumar, R.V., Sinha, V.R. (2012). Newer insights into the drug delivery approaches of α-glucosidase inhibitors. Expert Opinion on Drug Delivery, 9(4), 403-416. [CrossRef]
  6. Dash, R.P., Babu, R.J., Srinivas, N.R. (2018). Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus. Xenobiotica, 48(1), 89-108. [CrossRef]
  7. Datar, A.P., Jadhav, R.S. (2014). Development of pyrazole compounds as antidiabetic agent: A review. Letters in Drug Design & Discovery, 11(5), 686–703. [CrossRef]
  8. Firdaus, J.U., Siddiqui, N., Alam, O., et al. (2023). Pyrazole scaffold‐based derivatives: A glimpse of α‐glucosidase inhibitory activity, SAR, and route of synthesis. Archiv der Pharmazie, 356(5), 2200421. [CrossRef]
  9. Peytam, F., Adib, M., Shourgeshty, R., et al. (2020). Design and synthesis of new imidazo[1,2-b]pyrazole derivatives, in vitro α-glucosidase inhibition, kinetic and docking studies. Molecular Diversity, 24(1), 69-80. [CrossRef]
  10. Rikimaru, K., Wakabayashi, T., Abe, H., et al. (2012). A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: Design and synthesis of benzylpyrazole acylsulfonamides. Bioorganic & Medicinal Chemistry, 20(2), 714-733. [CrossRef]
  11. Griffith, D.A., Dow, R.L., Huard, K., et. al. (2013). Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure. Journal of Medicinal Chemistry, 56(17), 7110-7119. [CrossRef]
  12. Azimi, F., Ghasemi, J.B., Azizian, H., et. al. (2021). Design and synthesis of novel pyrazole-phenyl semicarbazone derivatives as potential α-glucosidase inhibitor: Kinetics and molecular dynamics simulation study. International Journal of Biological Macromolecules, 166, 1082-1095. [CrossRef]
  13. Azimi, F., Azizian, H., Najafi, M., et. al. (2021). Design, synthesis, biological evaluation, and molecular modeling studies of pyrazole-benzofuran hybrids as new α-glucosidase inhibitor. Scientific Reports, 11(1), 20776. [CrossRef]
  14. Barakat, A., Al-Majid, A.M., Soliman, S.M., et. al. (2017). Monoalkylated barbiturate derivatives: X-ray crystal structure, theoretical studies, and biological activities. Journal of Molecular Structure, 1141, 624-633. [CrossRef]
  15. Radhi, A.J., Zimam, E.H., Al-Mulla, E.A. (2022). Design, synthesis and α-glucosidase inhibitors evaluation of novel barbiturates based on carbohydrate. AIP Conference Proceedings, 2386(1), 030017. [CrossRef]
  16. Barakat, A., Islam, M.S., Al-Majid, A.M., et al. (2015). Synthesis, in vitro biological activities and in silico study of dihydropyrimidines derivatives. Bioorganic & Medicinal Chemistry, 23(20), 6740-6748. [CrossRef]
  17. Radhi, A.J., Zimam, E.H., Jafer, E.A. (2021). New barbiturate derivatives as potent in vitro α-glucosidase inhibitors. Egyptian Journal of Chemistry, 64(1), 117-123. [CrossRef]
  18. Deniz, E., Çöven, F.O., Ergüç, A., et al. (2025). Design, synthesis, and evaluation of benzoxazole-linked pyrazole hybrids as VEGFR-2-targeted antiproliferative agents. Cell Biochemistry and Biophysics, 83, 4961-4975. [CrossRef]
  19. Kuzu, B., Arzuk, E. (2025). Discovery of new pyrazole‐tosylamide derivatives as apoptosis inducers through BCL‐2 inhibition and caspase‐3 activation. Chemistry & Biodiversity, 22(2), e202401673. [CrossRef]
  20. Mortikov, V.Y., Rodinovskaya, L.A., Fedorov, A.E., et al. (2014). Synthesis of heterocyclic compounds from 4-formylpyrazoles. Russian Chemical Bulletin, 63, 443-456. [CrossRef]
  21. Gunasekaran, P., Yim, M.S., Ahn, M., et al. (2020). Development of a polo-like kinase-1 polo-box domain inhibitor as a tumor growth suppressor in mice models. Journal of Medicinal Chemistry, 63(23), 14905-14920. [CrossRef]
  22. Tao, Y., Zhang, Y., Cheng, Y., et al. (2013). Rapid screening and identification of α‐glucosidase inhibitors from mulberry leaves using enzyme‐immobilized magnetic beads coupled with HPLC/MS and NMR. Biomedical Chromatography, 27(2), 148-155. [CrossRef]
  23. Kuzu, B., Nalcı, K.A. (2025). In vitro assessment of antiproliferative properties of a novel benzoxazole-conjugated pyrrolotriazinone. International Journal of Chemical Technology, 9(1), 107-116. [CrossRef]
  24. Dabhi, A.S., Bhatt, N.R., Shah, M.J. (2013). Voglibose: an alpha glucosidase inhibitor. Journal of Clinical and Diagnostic Research, 7(12), 3023. [CrossRef]
  25. Sels, J.P.J., Huijberts, M.S., Wolffenbuttel, B.H. (1999). Miglitol, a new α-glucosidase inhibitor. Expert Opinion on Pharmacotherapy, 1(1), 149-156. [CrossRef]